Tirzepatide (Mounjaro®) was approved by the U.S. Food and Drug Administration (FDA) on May 13, 2022, for the treatment of type 2 diabetes. Due to the recent nature of the drug, there are not enough studies to show what long-term effects may be.
Is it safe to use Tirzepatide long-term?
